Clinical Trials Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Total 1453 results

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Thymic Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Rheumatoid Arthritis

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Enrolling by invitation

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Unknown

Study of KN046 With Chemotherapy in First Line Advanced NSCLC

Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

Advanced Solid Tumor

Australia
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

HER2-positive Metastatic Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Advanced Non-small Cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Not yet recruiting

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Breast Cancer | Gastric Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Lymphoma | Advanced Solid Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer

Squamous Non-small-cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Breast Cancer | Gastric/Gastroesophageal Junction Cancer

United States
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Advanced Gastrointestinal Tumors

China
Peking University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

HER2 Positive Solid Tumor

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Peking University

Completed

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

HER2-positive Solid Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Suzhou Kintor Pharmaceutical Inc,
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Solid Tumor

Taiwan
Weill Medical College of Cornell University
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

Thymic Carcinoma

United States
Alphamab Jilin Co., Ltd.

Unknown

Study on the Safety and Pharmacokinetics of LM001 and Gonal-F® in Healthy Women

Infertility, Female
Suzhou Alphamab Co., Ltd.

Recruiting

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

China
Suzhou Alphamab Co., Ltd.

Recruiting

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Knee Arthroplasty, Total

China
Suzhou Alphamab Co., Ltd.

Recruiting

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia

Hemophilia

China
Alphamab Jilin Co., Ltd.

Unknown

Single Dose Recombinant Human Follicle Stimulating Hormone Fc Husion Protein (KN015) in Healthy Volunteers

Infertility, Female

China
Alphamab (Australia) Co Pty Ltd.

Recruiting

First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Australia
Alphamab (Australia) Co Pty Ltd.

Unknown

Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Australia
Tasly Biopharmaceuticals Co., Ltd.

Recruiting

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Nonalcoholic Steatohepatitis

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

Subcutaneous Fat

United States, Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (ERUPTE)

Acute Pulmonary Embolism

China
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat

Subcutaneous Fat

Australia
Caliway Biopharmaceuticals Co., Ltd.

Recruiting

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Subcutaneous Fat

United States
Tasly Biopharmaceuticals Co., Ltd.

Recruiting

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PROST-2)

Acute Ischemic Stroke

China
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Subcutaneous Fat

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Subcutaneous Fat

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers

Subcutaneous Fat

Australia
Tasly Biopharmaceuticals Co., Ltd.

Completed

Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

Acute Ischaemic Stroke

China
Tasly Biopharmaceuticals Co., Ltd.

Completed

Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial (PROUD)

Acute Ischaemic Stroke

China
Caliway Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Dercum's Disease
Tasly Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Neoplasms Malignant

China
Caliway Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)

Cellulite

United States
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite

United States

Clinical Trials Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations